Cargando…

Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens

Antibody signatures may become sophisticated screening tools for early diagnosis and the development of personalized anticancer treatments. We used biopanning to enrich the immune response of head and neck squamous cell carcinoma (HNSCC) patients. This method revealed a HNSCC-specific antibody signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scanlon, Christina Springstead, D’Silva, Nisha J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654574/ https://www.ncbi.nlm.nih.gov/pubmed/23734304 http://dx.doi.org/10.4161/onci.23433

Ejemplares similares

Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013)

Targeting the tumor mutanome for personalized vaccination therapy
por: Kreiter, Sebastian, et al.
Publicado: (2012)

Approaching untargetable tumor-associated antigens with antibodies
por: Dao, Tao, et al.
Publicado: (2013)

In situ conversion of tumors into autologous tumor-associated antigen vaccines by intratumoral injection of α-gal glycolipids
por: Galili, Uri
Publicado: (2013)

Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs
por: Yi, Yongxiang, et al.
Publicado: (2012)

The antigen specific composition of melanoma tumor infiltrating lymphocytes?
por: Hadrup, Sine Reker
Publicado: (2012)

Antigen shedding into the circulation contributes to tumor immune escape
por: Höchst, Bastian, et al.
Publicado: (2012)

High-quality and high-avidity T cell clones specific for tumor-associated antigens and how to find them
por: Wilde, Susanne, et al.
Publicado: (2012)

HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens
por: Xu, Qing-Wen, et al.
Publicado: (2013)

Cancer testis antigens: A new paradigm for cancer therapy
por: Suri, Anil, et al.
Publicado: (2012)

Mimotope vaccine efficacy gets a "boost" from native tumor antigens
por: Buhrman, Jonathan D., et al.
Publicado: (2013)

Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy
por: Tsuji, Takemasa, et al.
Publicado: (2012)

Immunological profiling as a means to invigorate personalized cancer therapy
por: Hegmans, Joost PJJ, et al.
Publicado: (2013)

Tumor immune escape in acute myeloid leukemia: Class II-associated invariant chain peptide expression as result of deficient antigen presentation
por: van Luijn, Marvin M., et al.
Publicado: (2012)

Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages
por: Cavnar, Michael J, et al.
Publicado: (2014)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies
por: Omokoko, Tana, et al.
Publicado: (2015)

Activation of antigen-exposed iMC-DCs at the “right place” and “right time” promotes potent anti-tumor immunity
por: Spencer, David M.
Publicado: (2012)

The relationship between malignant and tumor-associated cells provides a new strategy for targeted diagnosis and therapy
por: Lu, Xiaoling, et al.
Publicado: (2013)

Bioreactors get personal
por: Somerville, Robert P.T., et al.
Publicado: (2012)

The role of tumor expression of CD200 in tumor formation, metastasis and susceptibility to T lymphocyte adoptive transfer therapy
por: Talebian, Fatemeh, et al.
Publicado: (2012)

Combining cellular and gene therapy approaches for treatment of intracranial tumors
por: Hickey, Michelle J, et al.
Publicado: (2013)

Revisiting glucose metabolism in cancer: lessons from a PKM knock-in model
por: Sato, Taku, et al.
Publicado: (2018)

Cytomegalovirus infection in brain tumors: A potential new target for therapy?
por: Söderberg-Nauclér, Cecilia, et al.
Publicado: (2012)

Rapamycin: A rheostat for CD8(+) T-cell-mediated tumor therapy
por: Srivastava, Rupesh K., et al.
Publicado: (2012)

Hypoxia and tumor-associated macrophages: A deadly alliance in support of tumor progression
por: Van Overmeire, Eva, et al.
Publicado: (2014)

A self antigen reopens the games in pancreatic cancer
por: Cappello, Paola, et al.
Publicado: (2013)

TEIPP peptides: exploration of unTAPped cancer antigens
por: Marijt, Koen A., et al.
Publicado: (2019)

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches
por: Maurer, Margarita, et al.
Publicado: (2012)

Personalizing immunotherapy: Balancing predictability and precision
por: Agur, Zvia, et al.
Publicado: (2012)

The many flavors of tumor-associated B cells
por: Marits, Per, et al.
Publicado: (2013)

Targeting tumor vulnerabilities associated with loss of heterozygosity
por: Rendo, Veronica, et al.
Publicado: (2020)

Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy
por: Lu, Yong, et al.
Publicado: (2014)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Personal neoantigen cancer vaccines: The momentum builds
por: Fritsch, Edward F, et al.
Publicado: (2014)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Modifying tumor-associated macrophages: An important adjunct to immunotherapy
por: Fridlender, Zvi G, et al.
Publicado: (2013)

Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells
por: Larmonier, Nicolas, et al.
Publicado: (2012)

RIPK3—a predictive marker for personalized immunotherapy?
por: Smola, Sigrun
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dfoov5a1va4qqcfm85empemqhe